Skip to content

AI-Supported Care Engagement for Next-step Delivery - Medicare Advantage

AI-Supported Care Engagement for Next-step Delivery - Medicare Advantage (ASCEND-MA)

Status
Enrolling by invitation
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07804095
Acronym
ASCEND-MA
Enrollment
9906
Registered
2026-09-04
Start date
2026-08-17
Completion date
2027-11-17
Last updated
2026-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient Navigation, Population Health Management

Keywords

Population Health, Care Navigation, Medicare Advantage, Artificial Intelligence, Clinical Decision Support, Care Management, Health Services Research, Chronic Disease Management, Risk Stratification, Preventative Care, Health Care Utilization, Health Care Costs

Brief summary

ASCEND-MA is an embedded, health-services study of at-risk Medicare Advantage members attributed to Intermountain Health in Utah. Participants are quasi-randomized based on their medical-record-number parity to either AI-supported, nurse-reviewed proactive care navigation or usual care. The study will evaluate whether the program changes cumulative payor-paid healthcare spending over 12 months.

Detailed description

An additional ancillary, separately consented consumer-experience sub-study will sample roughly 45 intervention-arm participants for surveys and interviews about the acceptability, burden, and perceived usefulness of the care-navigation workflow.

Interventions

OTHERAI-Supported Rising-Risk Care Navigation

AI-supported proactive care navigation involves the generation of guideline-informed candidate care-navigation actions from protocol-authorized structured data, human-in-the-loop review by a nurse, and then delivery of the approved suggestion through existing care-management or clinical workflows. The nurse may accept, modify, reroute, or reject each candidate before participant outreach or care-team routing. Reassessment is planned approximately every 90 days and may change intervention delivery, but not assigned-group membership.

Sponsors

Intermountain Health Care, Inc.
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Intervention model description

Eligible participants are quasi-randomized 1:1 at the individual level using medical-record-number parity.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

•.Enrolled in an eligible Medicare Advantage plan and attributed to Intermountain Health in Utah. * Continuous Medicare Advantage enrollment for at least 6 months before the index date. * PRM Rising-Risk score (an internally derived prediction model) of at least 0.70 and Current-Risk score below 0.95 at index * Predicted year-over-year cost increase of at least 30%. * At least one targeted chronic condition: diabetes mellitus, heart failure, chronic obstructive pulmonary disease, chronic kidney disease, hypertension, or hyperlipidemia.

Exclusion criteria

* Hospice enrollment at index. * End-stage renal disease requiring chronic dialysis at index. * Active oncology treatment at index. * Long-term institutional residence, including skilled-nursing-facility residence, at index. * Primary language cannot be supported through patient-directed outreach and no feasible alternative care-team communication pathway is available.

Design outcomes

Primary

MeasureTime frameDescription
Cumulative payer-paid health care spending per participant1 yearMean cumulative payer-paid health care spending (in U.S. dollars) recorded in claims per participant.

Secondary

MeasureTime frameDescription
Rate of All-Cause Acute-Care Episodes1 yearInpatient admissions, emergency department visits, and observation stays will be combined into acute-care episodes, with related encounters counted once.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 5, 2026